ASCO 2021 | 7-year follow-up of RESONATE-2 trial for CLL/SLL
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, gives an update on the Phase III RESONATE-2 trial, discussing data from up to 7 years of follow-up. This trial investigated using ibrutinib versus chlorambucil in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The rate of progression-free survival after 6.5 years was 61% in patients treated with ibrutinib and 9% in patients treated with chlorambucil. The rate of overall survival after 6.5 years among patients treated with ibrutinib was 78%. The data indicates that ibrutinib is an effective and well-tolerated treatment option for patients with CLL or SLL. Dr Ghia highlights findings from subgroup analysis and comments on the safety findings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
